



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

17 Feb 2020 (#8)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizek@sun.ac.za](mailto:lizek@sun.ac.za)

## Important Notice

- NIH participates in the [Global Alliance for Chronic Diseases \(GACD\)](#), a collection of publicly funded research agencies that supports innovative research collaborations to address the prevention and treatment of chronic diseases in vulnerable populations. The current GACD funding call focuses on implementation research proposals for the primary and secondary prevention of cancer in low- and middle-income countries (LMICs), and in populations facing conditions of vulnerability in high-income countries. NIH funding opportunity supporting this call for applications: [Notice of Special Interest \(NOSI\): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments \(NOT-CA-20-025\)](#). Submit applications using one of the following NIH funding opportunity announcements (FOAs). Applies to application due dates from 5 June 2020 to 8 May 2022.
  - Dissemination and Implementation Research in Health [\(R01 Clinical Trial Optional\) \(PAR-19-274\)](#)
  - Dissemination and Implementation Research in Health [\(R21 Clinical Trial Optional\) \(PAR-19-275\)](#)
  - Dissemination and Implementation Research in Health [\(R03 Clinical Trial Not Allowed\) \(PAR-19-276\)](#)

Proposals must focus on implementation research for the primary and/or secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in HICs. Proposals must build on evidence-based interventions (including cost-effectiveness) for the respective population groups under defined contextual circumstances. Research activities should focus on their implementation in real-life settings. The proposed interventions should be gender-responsive. The aim should be to adapt and scale-up the implementation of these intervention(s) in accessible, affordable and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers.

- [NOT-DK-20-010](#) Notice of Update to Research Priorities of [PAS-18-698](#), High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional).
- [NOT-DK-20-011](#) Notice of Update to Research Priorities of [PA-18-615](#), Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional)
- [NOT-TW-20-001](#) Notice of Change to update the Letters of Intent due date for 2020 for the Funding Opportunity Announcement [PAR-20-030](#) HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
- [NOT-AI-20-032](#) Notice of Intent to Publish a Funding Opportunity Announcement for Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed). The National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) intend to publish Funding Opportunity Announcements (FOAs) for the Martin Delaney Collaboratories (MDC) for HIV Cure Research program, a cooperative partnership between academia, industry, government, and community aimed at developing innovative strategies for cure or sustained remission of persistent HIV infection (<https://www.niaid.nih.gov/research/mdc>). Two separate FOA's will be issued: one will be a re-issue of the Martin Delaney Collaboratories for HIV Cure Research (UM1) FOA, and the other will be a new FOA for an

MDC focused specifically on HIV cure research in pediatric populations. Only new applications will be accepted under both FOAs; competitive renewal applications from existing awards will not be accepted. Applications will include both basic and applied (preclinical) research. Some aspect of clinical research must be included, however clinical trials will not be allowed in either FOA. Applicants will be encouraged to develop clinical trial protocols within the collaboration and to seek separate funding for implementation of the trials through NIAID HIV/AIDS Clinical Trial Networks, U01 grant applications, industry sponsorship, or support from other funding organizations. NIAID intends to fund 4-6 awards and intends to cap direct costs at \$3.5 million per year for each award. Estimated Publication Date of Funding Opportunity Announcement: 16 June 2020.

- **[NOT-CA-20-028](#) Notice of Intent to Publish a Funding Opportunity Announcement for Metastasis Research Network (U54 Clinical Trial Not Allowed).** This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The FOA is expected to be published in April 2020. The FOA will use the U54 activity code (Clinical Trial Not Allowed). The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states. Estimated Publication Date of Funding Opportunity Announcement: 15 April 2020. Estimated Total Funding: Up to \$7.5 million in fiscal year 2021. Expected Number of Awards: Five
- **[NOT-TW-20-002](#) Notice of Intent to Publish a Funding Opportunity Announcement for Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (U01).** Estimated Publication Date of Funding Opportunity Announcement: 1 July 2020. First Estimated Application Due Date: 4 November 2020. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects in anticipation of the linked FOAs. The overall objective of the Global Environmental and Occupational Health (GEOHealth) program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, training, curriculum and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats; and to support a global network of hubs that serves as a platform for coordinated research and training activities in environmental and occupational health. Applicants are encouraged to involve multiple U.S. and LMIC partner institutions in the proposed research project.
  - See the old/ previous FOA's:
    - [RFA-TW-14-001 Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health \(GEOHealth\) – Research \(U01\)](#)
    - [RFA-TW-14-002 Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health \(GEOHealth\) – Research Training \(U2R\).](#)
- **[NOT-AI-20-033](#) Pre-Solicitation Notice: NIAID Specimen Repository.** National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) conducts and supports epidemiological and clinical research on infectious diseases. Many of the large clinical and epidemiological studies funded by NIAID collect biologic specimens from subjects for ongoing and future studies. The collection and storage of these specimens from many different research studies in a single repository is a valuable resource with which researchers can rapidly validate scientific hypotheses and algorithms for clinical decision-making. Comprehensive and well-maintained specimen collections coupled with epidemiologic data have facilitated research on the pathogenesis of HIV disease, development of novel drug approaches, HIV prevention studies of potential microbicides and vaccines, and approaches for eliminating HIV reservoirs". The NIAID Specimen Repository (NSR), first funded in 1988, provides receipt, storage and distribution of biological specimens received from institutions conducting NIAID-sponsored clinical trials and observational cohort studies. Presently the repository largely houses specimens from HIV related clinical trials and cohort studies. The specimens have been collected over many years. Selection of Study Groups storing specimens in the NSR is guided by scientific priorities of NIAID. The current NIAID Study Groups storing specimens in the NSR are: the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS), now called the MACS/WIHS Combined Cohort Study (MWCCS); and the HIV Vaccine Trials Network (HVTN). The NSR also

maintains specimens from other smaller NIAID-sponsored studies that have been completed. There are currently over 8 million specimens in the NSR. The current contract with Precision Bioservices, Inc., Contract No. HHSN272201400037C, will expire on September 29, 2021. Duration of contract: 7 Years. The purpose of this contract is the short, moderate and long-term specimen storage of domestic and international clinical research specimens through receipt, cryopreservation, and storage of specimens from research sites or laboratories. Specimens include peripheral blood mononuclear cells, serum, plasma, tissue and other bodily fluids or substances such as cervicovaginal lavage (CVL), semen, saliva, urine, feces, autopsy and biopsy materials and whole blood spots dried on filter paper.

- It is anticipated this will be a performance-based acquisition and a cost reimbursement, term/level of effort, type of contract will be awarded.
- This RFP will be available electronically on/about February 20, 2020 and may be accessed through beta.SAM.gov.

- **[NOT-CA-20-025](#) Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments.** The purpose of this Notice is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs) and in low resource settings. This Notice also aligns with the [Global Alliance for Chronic Diseases](#) (GACD) 2020 Cancer Call. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. The research projects on which these applications will be based should be focused on dissemination and implementation research for the primary and secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in HICs. The projects described in grant applications must be built on evidence-based interventions (including cost-effectiveness) for the respective population groups under defined contextual circumstances. For promising interventions, a limited validation period can be envisaged. However, the core of the research activities should focus on their implementation in real-life settings. NCI is interested in proposed studies to adapt and scale-up the implementation of these interventions in accessible, affordable, and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this Notice.

- [PAR-19-274](#): Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- [PAR-19-275](#): Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- [PAR-19-276](#): Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

- **[NOT-MH-20-031](#) Notice of Special Interest to Highlight Research Priorities for Risk Algorithms Applications in Healthcare Settings to Improve Suicide Prevention.** NIMH held a meeting in June 2019 to identify and prioritize research needs in the application of predictive analytics in suicide prevention among healthcare providers. The meeting summary details research topics and gaps that included: biostatistical challenges, provider and patient understanding of risk algorithms, ethical considerations, needs for clinical decision tools to guide risk algorithm application, and policy-relevant research. NIMH is encouraging practice and deployment relevant applications proposed by multidisciplinary teams. This notice applies to due dates on or after 5 June 2020 and subsequent receipt dates through 8 September 2022.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105